// App-Quantinova.ai

79 : Effectiveness of High-Dose MTX Therapy for Adult Ph-Negative ALL By Randomized Trial: JALSG ALL202-O

Researchers

Presenter

  • Toru Sakura

Principal Investigators

  • Fumihiko Hayakawa

  • Isamu Sugiura

  • Shigeki Ohtake

  • Yukio Kobayashi

  • Keitaro Matsuo

  • Kiyotoshi Imai

  • Noriko Usui

  • Shin Fujisawa

  • Tohru Murayama

  • Toshiaki Yujiri

  • Hitoshi Kiyoi

  • Kazunori Ohnishi

  • Yasushi Miyazaki

Medical Centers

  • Japanese Red Cross Aichi Blood Center, Seto City, Japan

  • Leukemia Research Center, Saiseikai Maebashi Hospital, Gunma, Japan

  • Clinical Oncology and Hematology, The Jikei University School of Medicine, Tokyo, Japan

  • Department of Diagnostic Radiology, National Cancer Center Hospital, Tokyo, Japan

  • Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan

  • Department of Tumor and Diagnostic Pathology, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan

  • Department of Pathologic Oncology, Mie University Graduate School of Medicine, Mie, Japan

  • Clinical Laboratory Science, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan

  • Toyohashi Municipal Hospital, Toyohashi, Japan

  • Department of Gastroenterological Oncology, Hyogo Cancer Center, Akashi, Japan

  • Department of Gastroenterology, Sapporo Hokuyu Hospital, Sapporo, Japan

  • Third Department of Internal Medicine, Yamaguchi University School of Medicine, Yamaguchi, Japan

  • Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan

  • National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

  • Ph chromosome

Drug/Treatment

  • Methotrexate

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved